Cover Image
市場調查報告書

沙眼衣原體感染疾病- 開發中產品分析

Chlamydia Trachomatis Infections - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 321899
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
沙眼衣原體感染疾病- 開發中產品分析 Chlamydia Trachomatis Infections - Pipeline Review, H2 2014
出版日期: 2014年12月31日 內容資訊: 英文 38 Pages
簡介

沙眼衣原體感染疾病感染子宮頸部,尿道,直腸的表皮的革蘭氏陰性菌,有時也感染到眼睛或肺部等生殖器官以外部位的鹹染疾病。女性症狀有陰道異常、出血、排尿障礙等,男性則有尿道產生分泌物、搔癢感,排尿障礙等。

本報告提供沙眼衣原體感染疾病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

沙眼衣原體感染疾病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/實驗室

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:各大學/實驗室

治療藥的開發企業

  • ActivBiotics Pharma, LLC
  • Big DNA Ltd.
  • Foamix Pharmaceuticals Ltd.
  • Prokarium Ltd.

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BDNA-003
  • chlamydia trachomatis vaccine
  • chlamydia vaccine
  • minocycline Gel
  • rifalazil

最新的開發中產品資訊

產品開發的里程碑

  • 熱門新聞及新聞稿

附錄

圖表

目錄
Product Code: GMDHC5894IDB

Summary

Global Markets Direct's, 'Chlamydia Trachomatis Infections - Pipeline Review, H2 2014', provides an overview of the Chlamydia Trachomatis Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chlamydia Trachomatis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chlamydia Trachomatis Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chlamydia Trachomatis Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chlamydia Trachomatis Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chlamydia Trachomatis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chlamydia Trachomatis Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chlamydia Trachomatis Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chlamydia Trachomatis Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chlamydia Trachomatis Infections Overview
  • Therapeutics Development
    • Pipeline Products for Chlamydia Trachomatis Infections - Overview
    • Pipeline Products for Chlamydia Trachomatis Infections - Comparative Analysis
  • Chlamydia Trachomatis Infections - Therapeutics under Development by Companies
  • Chlamydia Trachomatis Infections - Therapeutics under Investigation by Universities/Institutes
  • Chlamydia Trachomatis Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Chlamydia Trachomatis Infections - Products under Development by Companies
  • Chlamydia Trachomatis Infections - Products under Investigation by Universities/Institutes
  • Chlamydia Trachomatis Infections - Companies Involved in Therapeutics Development
    • ActivBiotics Pharma, LLC
    • Big DNA Ltd.
    • Foamix Pharmaceuticals Ltd.
    • Prokarium Ltd.
  • Chlamydia Trachomatis Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BDNA-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • chlamydia trachomatis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • chlamydia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • minocycline Gel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rifalazil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Chlamydia Trachomatis Infections - Recent Pipeline Updates
  • Chlamydia Trachomatis Infections - Product Development Milestones
    • Featured News & Press Releases
      • Apr 26, 2010: Foamix is granted a fourth U.S. patent for OilGel, directed to pharmaceutical compositions and their dermatological, gynecological and ophthalmic applications
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chlamydia Trachomatis Infections, H2 2014
  • Number of Products under Development for Chlamydia Trachomatis Infections - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Comparative Analysis by Unknown Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Chlamydia Trachomatis Infections - Pipeline by ActivBiotics Pharma, LLC, H2 2014
  • Chlamydia Trachomatis Infections - Pipeline by Big DNA Ltd., H2 2014
  • Chlamydia Trachomatis Infections - Pipeline by Foamix Pharmaceuticals Ltd., H2 2014
  • Chlamydia Trachomatis Infections - Pipeline by Prokarium Ltd., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Chlamydia Trachomatis Infections Therapeutics - Recent Pipeline Updates, H2 2014

List of Figures

  • Number of Products under Development for Chlamydia Trachomatis Infections, H2 2014
  • Number of Products under Development for Chlamydia Trachomatis Infections - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Routes of Administration, H2 2014
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top